STCBIOSTCBIO
STCBIO
  • About Us
    • Business Philosophy
      • Business Ideology
      • Business Principles
      • Vision
      • CI
    • Founder
      • Kye-Ho Lee
      • Social Contribution
    • STC Introduction
      • STC LIFE
      • STC NARA
      • bBHC
      • 97.7 B&H
    • History
    • How to Find Us
  • Research & Development
    • STRI
    • New Drug Research & Development Center
    • Agricultural Life Science Research Center
    • Life Science R&D Center
    • Gene Research Center
  • Major Products
    • ENERGY WATER
    • Cell97.7
    • CELGEN
    • LAMU
    • EIS
    • Customized Cosmetics
    • Food Supplements
  • PR
    • STC in News
    • STC PR
Menu back  
 
  • CORPORATE SITE LinkedIn
  • LANGUAGE
    • ENGLISH
    • KOREAN
    • CHINESE
    • CORPORATE SITE LinkedIn
    • About Us
      • Business Philosophy
        • Business Ideology
        • Business Principles
        • Vision
        • CI
      • Founder
        • Kye-Ho Lee
        • Social Contribution
      • STC Introduction
        • STC LIFE
        • STC NARA
        • bBHC
        • 97.7 B&H
      • History
      • How to Find Us
    • Research & Development
      • STRI
      • New Drug Research & Development Center
      • Agricultural Life Science Research Center
      • Life Science R&D Center
      • Gene Research Center
    • Major Products
      • ENERGY WATER
      • Cell97.7
      • CELGEN
      • LAMU
      • EIS
      • Customized Cosmetics
      • Food Supplements
    • PR
      • STC in News
      • STC PR
    April 17, 2020NewsBy stcbio

    STRI PERFECTS STEM-CELL PLURIPOTENCY TO ENABLE 3D PRINTING OF HUMAN ORGANS





    [South China Morning Post] April 17th, 2020

    Within five years, the global stem cell market will exceed US $15 billion, prompting industry players to intensify research collaborations, and mergers and acquisitions to develop innovative solutions that could eradicate incurable diseases such as cancer or improve the life expectancy of ageing populations. In this highly competitive market, South Korea’s pioneering STC-Stem Cell Treatment & Research Institute (STRI) stands out with its breakthrough technology perfecting the pluripotency of stem cells….

    You can download the original article here | Go to page 4



    BACK
    Related posts
    Treatment of acute ischemic stroke by minimally manipulated umbilical cord-derived mesenchymal stem cells transplantation: A case report
    August 24, 2021
    Psoriasis treatment using minimally manipulated umbilical cord-derived mesenchymal stem cells: A case report
    August 24, 2021
    Alopecia treatment using minimally manipulated human umbilical cord-derived mesenchymal stem cells: Three case reports and review of literature
    August 24, 2021
    No title
    July 31, 2020
    460 patents regarding nEPS are registered in 147 countries.
    March 19, 2020
    STRI registered a patent for liver cell differentiation using the world’s first pluripotent stem cells without side effects (nEPS) at EU
    March 11, 2020
    PR
    • STC in News
    • STC PR
    • About Us
      • Business Philosophy
        • Business Ideology
        • Business Principles
        • Vision
        • CI
      • Founder
        • Kye-Ho Lee
        • Social Contribution
      • STC Introduction
        • STC LIFE
        • STC NARA
        • bBHC
        • 97.7 B&H
      • History
      • How to Find Us
    • Research & Development
      • STRI
      • New Drug Research & Development Center
      • Agricultural Life Science Research Center
      • Life Science R&D Center
      • Gene Research Center
    • Major Products
      • ENERGY WATER
      • Cell97.7
      • CELGEN
      • LAMU
      • EIS
      • Customized Cosmetics
      • Food Supplements
    • PR
      • STC in News
      • STC PR

    STC Group Co.,Ltd  |  72 UN Village-gil, Yongsan-gu Seoul (04420) South Korea
    TEL. 080-718-0120  |  FAX. 02-511-6419

    Copyright@2017 by STC Group Corporation Co.Ltd . All Rights reserved.

      • STRI
      • Energy water
      • All that skin
      Famliy Site